96 related articles for article (PubMed ID: 24969255)
21. Cancer pharmacogenomics: current and future applications.
Watters JW; McLeod HL
Biochim Biophys Acta; 2003 Mar; 1603(2):99-111. PubMed ID: 12618310
[TBL] [Abstract][Full Text] [Related]
22. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.
Michael M; Thompson M; Hicks RJ; Mitchell PL; Ellis A; Milner AD; Di Iulio J; Scott AM; Gurtler V; Hoskins JM; Clarke SJ; Tebbut NC; Foo K; Jefford M; Zalcberg JR
J Clin Oncol; 2006 Sep; 24(26):4228-35. PubMed ID: 16896007
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
[TBL] [Abstract][Full Text] [Related]
24. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
Taur SR; Kulkarni NB; Gandhe PP; Thelma BK; Ravat SH; Gogtay NJ; Thatte UM
J Postgrad Med; 2014; 60(3):265-9. PubMed ID: 25121365
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan pharmacogenetics: a finished puzzle?
Phelps MA; Sparreboom A
J Clin Oncol; 2014 Aug; 32(22):2287-9. PubMed ID: 24958823
[No Abstract] [Full Text] [Related]
26. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
[TBL] [Abstract][Full Text] [Related]
27. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
28. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Innocenti F; Ratain MJ
Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
[TBL] [Abstract][Full Text] [Related]
30. Identification of the effects of pathogenic genetic variations of human
Avsar O
Nucleosides Nucleotides Nucleic Acids; 2024; 43(4):356-376. PubMed ID: 37747773
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
32. [SNPs associated with adverse effects].
Isomura M; Miki Y
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1908-13. PubMed ID: 16282725
[TBL] [Abstract][Full Text] [Related]
33. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
Dorado P; López-Torres E; Peñas-Lledó EM; Martínez-Antón J; Llerena A
Pharmacogenomics J; 2013 Aug; 13(4):359-61. PubMed ID: 22641027
[TBL] [Abstract][Full Text] [Related]
34. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
Kirchheiner J; Nickchen K; Bauer M; Wong ML; Licinio J; Roots I; Brockmöller J
Mol Psychiatry; 2004 May; 9(5):442-73. PubMed ID: 15037866
[TBL] [Abstract][Full Text] [Related]
36. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Biason P; Masier S; Toffoli G
J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
[TBL] [Abstract][Full Text] [Related]
37. Bioluminescence Measurement of Time-Dependent Dynamic Changes of CYP-Mediated Cytotoxicity in CYP-Expressing Luminescent HepG2 Cells.
Iwado S; Abe S; Oshimura M; Kazuki Y; Nakajima Y
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799598
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomic applications in oncology.
Walko CM; Ikediobi O
J Pharm Pract; 2012 Aug; 25(4):439-46. PubMed ID: 22907843
[TBL] [Abstract][Full Text] [Related]
39. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
[TBL] [Abstract][Full Text] [Related]
40. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]